[go: up one dir, main page]

NO20080495L - PEG-IFN-alfa og ribavirin for HBV-behandling - Google Patents

PEG-IFN-alfa og ribavirin for HBV-behandling

Info

Publication number
NO20080495L
NO20080495L NO20080495A NO20080495A NO20080495L NO 20080495 L NO20080495 L NO 20080495L NO 20080495 A NO20080495 A NO 20080495A NO 20080495 A NO20080495 A NO 20080495A NO 20080495 L NO20080495 L NO 20080495L
Authority
NO
Norway
Prior art keywords
ifn
peg
ribavirin
alpha
hbv treatment
Prior art date
Application number
NO20080495A
Other languages
English (en)
Inventor
Henricus Leonardus Antonius Janssen
Nigel Pluck
Matei Popescu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37654895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080495(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20080495L publication Critical patent/NO20080495L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer anvendelse av PEG-IFN-?-konjugater sammen med ribavirin for behandling av kroniske hepatitt B-infeksjoner. Foreliggende oppfinnelse tilveiebringer også en fremgangsmåte for behandling av kroniske hepatitt B-infeksjoner hos pasienter med behov for slik behandling, omfattende administrering av en mengde PEG-IFN-?-konjugat, sammen med en mengde ribavirin, som er effektiv for å behandle kronisk hepatitt B.
NO20080495A 2005-08-15 2008-01-28 PEG-IFN-alfa og ribavirin for HBV-behandling NO20080495L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107473 2005-08-15
PCT/EP2006/065026 WO2007020195A2 (en) 2005-08-15 2006-08-03 Peg-ifn alpha and ribavirin for hbv treatment

Publications (1)

Publication Number Publication Date
NO20080495L true NO20080495L (no) 2008-03-10

Family

ID=37654895

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080495A NO20080495L (no) 2005-08-15 2008-01-28 PEG-IFN-alfa og ribavirin for HBV-behandling

Country Status (16)

Country Link
US (2) US20070071720A1 (no)
EP (1) EP1917037A2 (no)
JP (1) JP2009504706A (no)
KR (1) KR20080027944A (no)
CN (1) CN101242857A (no)
AR (1) AR057746A1 (no)
AU (1) AU2006281498A1 (no)
BR (1) BRPI0614863A2 (no)
CA (1) CA2617958A1 (no)
IL (1) IL188962A0 (no)
MX (1) MX2008002015A (no)
NO (1) NO20080495L (no)
RU (1) RU2008109649A (no)
TW (1) TW200740455A (no)
WO (1) WO2007020195A2 (no)
ZA (1) ZA200801248B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2412730B1 (en) * 2009-03-27 2014-09-10 JW Pharmaceutical Corporation Interferon-alpha (ifn-alpha ) fused protein having ifn-alpha and cytoplasmic transduction peptide (ctp)
IN2015DN01371A (no) * 2012-08-13 2015-07-03 Jw Creagene Inc
WO2018232330A1 (en) * 2017-06-16 2018-12-20 Arbutus Biopharma Corporation Therapeutic compositions and methods for treating hepatitis b

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
PL192364B1 (pl) * 1998-06-08 2006-10-31 Hoffmann La Roche Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną
BR0314259A (pt) * 2002-09-13 2005-07-26 Idenix Cayman Ltd ß-l-2'-desoxinucleosìdeos para o tratamento de cepas de hbv resistentes e terapias combinadas
ES2477118T3 (es) * 2002-11-18 2014-07-15 Polaris Group Método para inhibir la replicaci�n viral in vivo
WO2005067963A1 (en) * 2003-12-23 2005-07-28 Intermune, Inc. Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
WO2006010256A1 (en) * 2004-07-26 2006-02-02 Transition Therapeutics Inc. Compositions and methods comprising vitamin b12 and an impdh inhibitor for treating viral, inflammatory and proliferative diseases
JP2008509902A (ja) * 2004-08-13 2008-04-03 ミジェニックス インコーポレイテッド Ｈｅｐａｄｎａｖｉｒｉｄａｅ感染を処置または防止するための組成物および方法
KR20070100237A (ko) * 2004-10-29 2007-10-10 바이오크리스트 파마수티컬즈, 인코퍼레이티드 치료용 푸로피리미딘 및 티에노피리미딘
WO2006050421A1 (en) * 2004-11-02 2006-05-11 New River Pharmaceuticals Inc. Prodrugs of ribavirin with improved hepatic delivery
CA2608709A1 (en) * 2005-05-31 2006-12-07 Novartis Ag Treatment of liver diseases in which iron plays a role in pathogenesis

Also Published As

Publication number Publication date
EP1917037A2 (en) 2008-05-07
WO2007020195A3 (en) 2007-05-24
CN101242857A (zh) 2008-08-13
US20070071720A1 (en) 2007-03-29
ZA200801248B (en) 2008-11-26
MX2008002015A (es) 2008-03-25
RU2008109649A (ru) 2009-09-27
JP2009504706A (ja) 2009-02-05
WO2007020195A2 (en) 2007-02-22
AR057746A1 (es) 2007-12-12
US20080317714A1 (en) 2008-12-25
TW200740455A (en) 2007-11-01
KR20080027944A (ko) 2008-03-28
IL188962A0 (en) 2008-08-07
AU2006281498A1 (en) 2007-02-22
BRPI0614863A2 (pt) 2011-04-19
CA2617958A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
CY1112560T1 (el) Πνευμονικη μεταφορα των αμινογλυκοσιδων
CY1120022T1 (el) Θεραπεια παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας
NO20072733L (no) Doseformer
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
DK1853250T3 (da) Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
WO2007111866A3 (en) Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
LT2878297T (lt) Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
DK1789419T3 (da) Gyraseinhibitorer og anvendelser deraf
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
NO20080351L (no) Anvendelse av sanglifehrin i HCV
NL1025873A1 (nl) Doseringsvormen en wijzen van behandeling met vegfr-remmers.
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
DK1663347T3 (da) Afereseindretning
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
NO20071706L (no) Koadministrering av Tigecycline og Digoxin.
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
NO20080495L (no) PEG-IFN-alfa og ribavirin for HBV-behandling
DK1603584T3 (da) Aplidine til behandling af multipelt myelom
ATE433459T1 (de) Desoxo-nonadepsipeptide
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
MY166063A (en) Intravenous antiviral treatments
GB0220257D0 (en) Vaccine
AP2248A (en) Treatment of HI-virus infections with oxidised blood proteins.
EA200700878A1 (ru) Лечение или предупреждение геморрагических вирусных инфекций с помощью иммуномодулирующих соединений

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application